The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest ...
Lower risk for foot disease driven by lower risk for neuropathy for new users of SGLT-2 inhibitors versus GLP-1 receptor agonists.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback